Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
/in International Publications, Newcastle Disease Virus /von 2017-12-20 / Trends Immunol. 2018 03;39(3):209-221Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature
/in Dendritic Cells, International Publications, Newcastle Disease Virus, Urothelial Carcinoma /von 2017-10-19 / Eur Urol Focus 2018 04;4(3):442-454Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
/in Checkpoint-Inhibitors, Glioblastoma, International Publications, Newcastle Disease Virus /von 2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-69Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2017-09-19 / J. Biotechnol. 2017 Oct;260:91-97Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2017-09-13 / Int. J. Cancer 2017 12;141(12):2505-2516Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
/in International Publications, Newcastle Disease Virus /von 2017-09-08 / Front Oncol 2017;7:195Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-235Oncolytic Viral Therapy for Mesothelioma
/in International Publications, Malignant Pleural Mesothelioma, Newcastle Disease Virus /von 2017-08-24 / Front Oncol 2017;7:179Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
/in Checkpoint-Inhibitors, Glioblastoma, International Publications, Newcastle Disease Virus /von 2017-08-14 / Cancer Cell 2017 08;32(2):253-267.e5
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de